Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights - Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escalation study now expected in Q2 2024, ahead of previous guidance - - Strong balance sheet with cash runway into fourth qua ...